Treatment of Intrauterine Growth Restriction With Low Molecular Heparin.

PHASE3CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 25, 2018

Primary Completion Date

April 30, 2022

Study Completion Date

February 19, 2023

Conditions
Intrauterine Growth Restriction
Interventions
DRUG

Low molecular weight heparin

Patients included in this study group will receive 3,500 IU / 0.2 ml / day of Bemiparina sc, from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).

DRUG

Placebos

Patients included in this study group will placebo (same presentation as the active drug), from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).

Trial Locations (1)

08950

Hospital Sant Joan de Déu, Esplugues de Llobregat

All Listed Sponsors
collaborator

Servicio de Asesoría a la Investigación y Logística SL

OTHER

lead

Fundació Sant Joan de Déu

OTHER

NCT03324139 - Treatment of Intrauterine Growth Restriction With Low Molecular Heparin. | Biotech Hunter | Biotech Hunter